Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product

INTRODUCTION: ABP 798 is being developed as a biosimilar to rituximab reference product (RP), a CD20-directed cytolytic antibody that is approved in the US and EU for the treatment of non-Hodgkin lymphoma (NHL). METHODS: This randomized, double-blind, comparative clinical study (JASMINE) evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Niederwieser, Dietger, Hamm, Caroline, Cobb, Patrick, Mo, Mindy, Forsyth, Cecily, Tucci, Alessandra, Hanes, Vladimir, Delwail, Vincent, Hajek, Roman, Chien, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568694/
https://www.ncbi.nlm.nih.gov/pubmed/33044684
http://dx.doi.org/10.1007/s11523-020-00748-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568694/
https://www.ncbi.nlm.nih.gov/pubmed/33044684
http://dx.doi.org/10.1007/s11523-020-00748-4

Ejemplares similares